Skip to main
CAPR

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Capricor Therapeutics (CAPR) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Capricor Therapeutics is projected to see a 50% upside in a positive outcome on October 3rd, which aligns with their 90% powered HOPE-3 trial 1.1 point difference, revealing a 1.2 point difference in decline for the PUL 2.0 at 12 months. Additionally, the Lancet publication reports significantly improved LVEF results, especially in patients with baseline cardiomyopathy, which supports Capricor's BLA amendment and request for a refined indication. Based on this information, the company's high revenue potential and potential for approval and partnership makes it a strong buy with a target price of $25.

Bears say

Capricor Therapeutics is facing significant regulatory risks with uncertainties in the approval pathway for Deramiocel, its allogenic cell therapy. The recent AdCom and lack of clarity on the sufficiency of data for a regulatory filing raise concerns about the viability of Deramiocel's approval. The company's upcoming WMS presentation of HOPE-3 data, if positive, could potentially redirect the narrative towards the upper-limb indication. However, the need for unprecedented agency action and the company's current financials indicate a negative outlook.

Capricor Therapeutics (CAPR) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Capricor Therapeutics (CAPR) Forecast

Analysts have given Capricor Therapeutics (CAPR) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Capricor Therapeutics (CAPR) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Capricor Therapeutics (CAPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.